Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?

被引:26
作者
Itakura, Haruka
Sobel, Burton E.
Boothroyd, Derek
Leung, Lawrence L.
Iribarren, Carlos
Go, Alan S.
Fortmann, Stephen P.
Quertermous, Thomas
Hlatky, Mark A.
机构
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Univ Vermont, Sch Med, Burlington, VT 05405 USA
[3] Kaiser Permanente No Calif, Div Res, Oakland, CA USA
[4] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA
关键词
D O I
10.1016/j.ahj.2007.09.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Circulating concentrations of proteins associated with coagulation and fibrinolysis may differ between individuals with coronary artery disease. (CAD) who develop an acute myocardial infarction (AMI) rather than stable exertional angina. Methods We compared plasma concentrations of fibrinogen, d-dimer, tissue-type plasminogen activator, and plasminogen activator inhibitor-1 (PAI-1) between patients whose first clinical manifestation of CAD was an AMI (n = 198) rather than stable exertional angina (n = 199). We also compared plasma concentrations of these proteins between patients with symptomatic CAD (either AMI or stable angina; n = 397) and healthy, control subjects (n = 197) to confirm the sensitivity of these assays to detect epidemiologic associations. Results At a median of 15 weeks after presentation, patients I with AMI had slightly higher d-dimer concentrations than patients with stable angina (P = .057), but were not significantly different in other markers. By contrast, fibrinogen, d-dimer, and tissue-type plasminogen activator were significantly higher (P < .001) and PAI-1 lower in patients with CAD than in healthy control subjects. After statistical adjustment for clinical covariates, cardiac risk factors, medications, and other confounders, fibrinogen, d-dimer, and PAI-1 remained significantly associated with CAD. Conclusion Selected plasma markers of coagulation and fibrinolysis did not distinguish patients presenting with AMI from those with stable exertional angina.
引用
收藏
页码:1059 / 1064
页数:6
相关论文
共 16 条
[1]   CIRCADIAN VARIATION OF FIBRINOLYTIC-ACTIVITY IN BLOOD [J].
ANDREOTTI, F ;
KLUFT, C .
CHRONOBIOLOGY INTERNATIONAL, 1991, 8 (05) :336-351
[2]   Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina [J].
Bogaty, P ;
Poirier, P ;
Simard, S ;
Boyer, L ;
Solymoss, S ;
Dagenais, GR .
CIRCULATION, 2001, 103 (25) :3062-3068
[3]   Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy [J].
Cesari, M ;
Rossi, GP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (06) :1378-1386
[4]   Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality - An individual participant meta-analysis [J].
Danesh, J ;
Lewington, S ;
Thompson, SG ;
Lowe, GDO ;
Collins, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (14) :1799-1809
[5]  
Folsom AR, 2001, THROMB HAEMOSTASIS, V86, P366
[6]   Prospective study of fibrinolytic factors and incident coronary heart disease - The Atherosclerosis Risk in Communities (ARIC) Study [J].
Folsom, AR ;
Aleksik, N ;
Park, E ;
Salomaa, V ;
Juneja, H ;
Wu, KK .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (04) :611-617
[7]   IMPAIRED FIBRINOLYSIS IN CORONARY-ARTERY DISEASE [J].
FRANCIS, RB ;
KAWANISHI, D ;
BARUCH, T ;
MAHRER, P ;
RAHIMTOOLA, S ;
FEINSTEIN, DI .
AMERICAN HEART JOURNAL, 1988, 115 (04) :776-780
[8]   Statin and β-blocker therapy and the initial presentation of coronary heart disease [J].
Go, AS ;
Iribarren, C ;
Chandra, M ;
Lathon, PV ;
Fortmann, SP ;
Quertermous, T ;
Hlatky, MA .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (04) :229-238
[9]  
HAMSTEN A, 1987, LANCET, V2, P3
[10]   Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris [J].
JuhanVague, I ;
Pyke, SDM ;
Alessi, MC ;
Jespersen, J ;
Haverkate, F ;
Thompson, SG .
CIRCULATION, 1996, 94 (09) :2057-2063